The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3β

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 2, 2006, Pages

  Gross, Eric R ^a   Hsu, Anna K ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Glycogen synthase kinase; Infarct size; Janus activated kinase; Morphine; Opioids

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; FENTANYL ISOTHIOCYANATE; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE; JANUS KINASE 2; MORPHINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OPIATE; PROTEIN KINASE B; STAT PROTEIN; STAT3 PROTEIN;

ANIMAL MODEL; ARTICLE; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; HEMODYNAMICS; ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOTONIC AGENTS; CELL LINE; ENZYME INHIBITORS; FENTANYL; GLYCOGEN SYNTHASE KINASE 3; HEMODYNAMIC PROCESSES; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; MALE; MORPHINE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NARCOTICS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 33746859331     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00003.2006     Document Type: Article

References (36)

1. Bolli R, Dawn B, and Xuan YT. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13: 72-79, 2003.
2. Booz GW, Day JN, and Baker KM. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34: 1443-1453, 2002.
3. Carvalho CR, Carvalheira JB, Lima MH, Zimmerman SF, Caperuto LC, Amanso A, Gasparetti AL, Meneghetti V, Zimmerman LF, Velloso LA, and Saad MJ. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144: 638-647, 2003.
4. Cieslik K, Abrams CS, and Wu KK. Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway. J Biol Chem 276: 1211-1219, 2001.
5. Fryer RM, Wang Y, Hsu AK, Nagase H, and Gross GJ. Dependence of delta1-opioid receptor-induced cardioprotection on a tyrosine kinase-dependent but not a Src-dependent pathway. J Pharmacol Exp Ther 299: 477-482, 2001.
6. Gross ER, Hsu AK, and Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94: 960-966, 2004.
7. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, and Das DK. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33: 1929-1936, 2001.
8. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Woller KC, and Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95: 187-195, 2004.
9. ATP channel in preconditioning (Abstract). J Mol Cell Cardiol 35: A21, 2003.
10. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, and Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549, 2004.
11. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Kishimoto T, and Yamuchi-Takihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 97: 315-319, 2000.
12. Leonard WJ and O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322, 1998.
13. Lo RK and Wong YH. Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. Mol Pharmacol 65: 1427-1439, 2004.
14. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, and Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648, 1996.
15. Mocanu MM and Yellon DM. p53 Down-regulation: a new molecular mechanism involved in ischaemic preconditioning. FEBS Lett 555: 302-306, 2003.
16. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T, and Yamauchi-Takihara K. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47: 797-805, 2000.
17. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, and Yamauchi-Takihara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104: 979-981, 2001.
18. Nguyen MH, Ho JM, Beattie BK, and Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem 276: 32704-32713, 2001.
19. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, and Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 276: 1418-1420, 1997.
20. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, and Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci USA 94: 11345-11350, 1997.
21. Stephanou A, Brar BK, Knight RA, and Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7: 329-330, 2000.
22. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, Knight RA, and Latchman DS. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 275: 10002-10008, 2000.
23. Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA, and Latchman DS. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem 276: 28340-28347, 2001.
24. Stephanou A, Scarabelli TM, Townsend PA, Bell R, Yellon D, Knight RA, and Latchman DS. The carboxyl-terminal activation domain of the STAT-1 transcription factor enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J 16: 1841-1843, 2002.
25. Suzuki S, Chuang LF, Doi RH, and Chuang RY. Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling. Biochem Biophys Res Commun 308: 802-808, 2003.
26. Takahashi T, Fukuda K, Pan J, Kodama H, Sano M, Makino S, Kato T, Manabe T, and Ogawa S. Characterization of insulin-like growth factor-1-induced activation of the JAK/STAT pathway in rat cardiomyocytes. Circ Res 85: 884-891, 1999.
27. Tsang A, Housenloy DJ, Mocanu MM, and Yellon MM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232, 2004.
28. Turenne GA and Price BD. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol 2: 12-21, 2001.
29. Verma A, Kambhampati S, Parmar S, and Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 22: 423-34, 2003.
30. Wang LH, Kirken RA, Erwin RA, Yu CR, and Farrar WL. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2 mediated T cell respons. J Immunol 162: 3897-3904, 1999.
31. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, and Jope RS. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278: 48872-48879, 2003.
32. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV, and Jope RS. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 99: 7951-7955, 2002.
33. Wen TC, Peng H, Hata R, Desaki J, and Sakanaka M. Induction of phosphorylated-Stat3 following focal cerebral ischemia in mice. Neurosci Lett 303: 153-156, 2001.
34. Xuan YT, Guo Y, Han H, Zhu Y, and Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98: 9050-9055, 2001.
35. Yoshioka S, Okimura Y, Takahashi Y, Iida K, Kaji H, Matsui M, and Chihara K. Up-regulation of mitochondrial transcription factor 1 mRNA levels by GH in VSMC. Life Sci 74: 2097-2109, 2004.
36. Zhang X, Shan P, Alam J, Fu XY, and Lee PJ. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a PI3K/Akt and p38 kinase dependent STAT3 pathway during anoxia-reoxygenation injury. J Biol Chem 280: 8714-8721, 2005.